Preeclampsia Clinical Trial
Official title:
The Study of Prevention and Intervention Strategy of Gestational Diseases Based on Cohort
Preeclampsia (PE) is one of a common type of hypertensive disorder complicating pregnancy
(HDCP). It is a class of clinical syndromes which shows relevant symptoms, hypertension and
proteinuria after 20 weeks pregnant as main characteristic, and may accompany with fetal
anomaly and systemic multi-system organs damage. Several complications, such as eclamptic
seizures, coma, intracranial hemorrhage (ICH), cardiac failure, pneumonedema, hepatic
failure, kidney failure, placental abruption and disseminated intravascular coagulation
(DIC), may be threat to the life of the mother as well as fetal. Thus, the disease is one of
the core issues that cause the maternal and perinatal death. Morbidity of PE is approximately
3% to 5%. Morbidity has significant differences between different populations. According to
the data, from 1995 to 2004, HDCP morbidity in four hospitals in Guangzhou was 5.78%, and in
the HDCP, mild preeclampsia and severe preeclampsia were accounted for 72.22% and 27.78%
respectively. Meanwhile, HDCP morbidity decreased from 9.4% (1984 to 1989) to 5.57% (1989 to
1998).
In 1996, the American Congress of Obstetricians and Gynecologists (ACOG) gave new
classification of HDCP based on the characteristic of disease symptoms, divide into five
groups; gestational hypertension, preeclampsia, eclampsia, chronic hypertension complicated
with preeclampsia and chronic hypertension. The pathogenesis of PE remains unclear so far.
The frequent sight is that PE caused by multiple reactions by a number of factors affect.
Physiologically, mainly altered of PE is increased blood viscosity and systemic vascular
spasm which cause hypoxic-ischemic of multiple key organs, such as the placenta, kidney,
liver and brain. The research theory includes abnormal trophoblast invasion, immune response
abnormal or increase, genetic susceptibility, coagulation disorders or thrombophilia,
abnormal angiogenesis, endothelial cell damage, abnormal levels of carbonic oxide, increase
of oxygen radical, abnormal metabolism of calcium ion, heterotrophia and so on. However,
there are numbers of epidemiologic study have analyzed high risk factor of PE which provides
significant medical evidence of prevention, early diagnosis and early treatment for PE, there
is only little study focus on susceptibility gene and pathogenic genetic variation. Nowadays,
there are numerous clinical phenotype are considered to exist, different phenotype gives
different inheritance and epigenetics. Thus, the investigator's group will examine the onset
of type and characteristics of PE by a retrospective cohort study to discuss if
susceptibility gene and pathogenic genetic variation were existing in PE patients, also to
find the relativity between clinical phenotype and genotype. Moreover, this study is trying
to reach the effect of PE on the patients' health as well as their children. Thus, can
predict the health status of PE patients and their children, and so can prevent (avoid or
delay) of the patients from late complications and disease in their children.
1. All female staff that works, examination and delivery in the Third Affiliated Hospital
of Guangzhou Medical University from Dec 1995 to Dec 2016 should be in the cohort.
Collect all information; include clinical examination and medical examination, science
the subject work in the hospital. Collect the perinatal data; include obstetric
information, past medical history, family history and so on. Build the database and
analyze the relative factor.
2. From all subjects, choose subjects that have got PE before as the experimental group.
Pair the same age, gestational weeks, children's gender and healthy subject as a control
group in the ratio of 1:1. The control group should exclude subject that have ever got
heart or lung diseases, diabetes, chronic nephrosis, immune disease and other hereditary
disease. Store the blood samples (serum, blood and plasma) of both the experimental
group and control group and their children. Compare the differences of functional
parameter between two groups both before and after delivery, which include blood
pressure, blood glucose and blood lipids. Moreover, compare the function of heart, liver
and kidney and genetic material (DNA and RNA).
3. Diagnostic standard of PE refer to People's Medical Publishing House <Obstetrics and
Gynecology> 8th edition. Confirm the diagnostic standard of HDCP and relative disease
include PE will make sure the veracity and uniformity of diagnosis.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03510286 -
Validation of a PrCr Dipstick Diagnostic Test in Ghana
|
||
Recruiting |
NCT03313024 -
Berlin-Brandenburg Pregnancy Cohort
|
||
Active, not recruiting |
NCT04990141 -
Molecular Screening Method for Preeclampsia (PREMOM)
|
||
Completed |
NCT02147626 -
Heart Health 4 Moms Trial to Reduce CVD Risk After Preeclampsia
|
N/A | |
Not yet recruiting |
NCT05999851 -
Multiparametric Assessment of Maternal Vascular Function in the Prediction of Hypertensive Disorders of Pregnancy
|
N/A | |
Recruiting |
NCT02923206 -
Proof-of-Concept Trial on Selective Removal of sFlt-1 in Pregnant Women With Preeclampsia Via Apheresis
|
N/A | |
Completed |
NCT02854501 -
Second Trimester Maternal Serum Homocysteine Levels and Uterine Artery Doppler for Prediction of Preeclampsia and Placentation Disorders
|
||
Withdrawn |
NCT05016440 -
Lisinopril for Renal Protection in Postpartum Preeclamptic Women
|
N/A | |
Completed |
NCT02554604 -
Identifying HDL Composition and Function in Preeclamptic and Normal Pregnancies
|
||
Completed |
NCT02384226 -
User Testing and Feedback for a Mobile Health Program for Postpartum Women: A Pilot Study
|
||
Terminated |
NCT02558023 -
The Treatment of Hypertension Associated With Severe Preeclampsia (PE). A Trial of Urapidil Versus Nicardipine
|
Phase 3 | |
Not yet recruiting |
NCT02541110 -
Prediction of Preeclampsia & Other Obstetric Complications by Serum Homocysteine & Doppler
|
N/A | |
Recruiting |
NCT02247297 -
Pancreatic Stone Protein (PSP) in Pregnant Women
|
||
Recruiting |
NCT02337049 -
Preeclampsia Subtypes and Surrogate Markers of CVD Risk
|
N/A | |
Completed |
NCT02238704 -
Cornell University-Micronutrient Initiative Calcium Supplementation Study
|
N/A | |
Completed |
NCT01195441 -
Prediction and Prevention of Preeclampsia by First Trimester Ultrasound
|
N/A | |
Withdrawn |
NCT01179542 -
The Involvement of Eukaryotic Translation Initiation Factor 4E (eIF4E) in Human Placental Implantation and in the Pathological Pregnancies: Preeclampsia and IUGR
|
N/A | |
Completed |
NCT00456118 -
Study of the Role of Tissular Maternofetal Alloimmunization in Placentation Pathologies
|
||
Recruiting |
NCT00117546 -
Cardiovascular and Autonomic Reactivity in Women With a History of Pre-eclampsia
|
Phase 4 | |
Completed |
NCT00787241 -
Platelet Count Trends in Pre-eclamptic Parturients
|
N/A |